HER2-Type cancers are primarily driven by the HER2 receptor pathway. This molecular subtype does not always align with IHC- or FISH-derived HER2 results but HER2-Type patients have excellent response to HER2-targeted therapies in the neoadjuvant setting. In fact, with advances in therapeutics, HER2-Type patients have good long term outcomes when treated with HER2-targeted agents.
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
